Pharnext : receives a new offer valuing its drug candidate for Charcot-Marie-Tooth disease type 1A at more than €500m and the support of its financial partners -October 30, 2023 at 03:41 am EDT

PARIS, France, October 30, 2023, 08:30 am CET - Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases...

Related Keywords

Macau ,Hong Kong ,France ,China ,Taiwan ,Paris ,France General ,Hugo Brugi , ,Tasly Pharmaceutical ,Greater China ,Mainland China ,Global Tech Opportunities ,Charcot Marie Tooth Disease Type ,Markets ,